Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults

Published on 10 Feb 2025
Last Updated on 10 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Pneumococcal conjugate vaccine 20-valent (PCV20) 0.5 mL suspension for injection in pre-filled syringe for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae for all adults aged 65 years and older, and other adults aged 18 to 64 years who are at increased risk for pneumococcal disease.

Funding status

PCV20 0.5 mL suspension for injection in pre-filled syringe is recommended for inclusion on the MOH Subsidised Vaccine List (SVL) for the abovementioned indication from September 2025.

Subsidy does not apply to pneumococcal conjugate vaccine 15-valent (PCV15).

Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults (10 Feb 2025) [PDF, 140 KB]

PES Pneumococcal conjugate vaccines for preventing pneumococcal disease in adults (10 Feb 2025) [PDF, 81 KB]